Background: Use of the electronic health record (EHR) is expected to increase rapidly in the near future, yet little research exists on whether analyzing internal EHR data using flexible, adaptive statistical methods could improve clinical risk prediction. Extensive implementation of EHR in the Veterans Health Administration provides an opportunity for exploration.
H eart attack and stroke are the first and fourth leading causes of death in the United States and together cost nearly $300 billion annually. 1 Further, cardiac risk is a major predictor of treatment benefit 2 and plays a central role in treatment guidelines for cardiovascular medication use 3, 4 and diagnostic testing. 5 Thus, accurate prediction of cerebrovascular and cardiovascular (CCV) risk in individual patients is a major clinical and research focus, bringing with it critical implications for physician decision making and for research on comparative and cost effectiveness. 6 Risk prediction is no simple task, however, particularly as it is dependent on both the quality and amount of available data and on statistical methods used for estimation. Although there is a great deal of research in the development of new tests to help assess cardiovascular risk, [7] [8] [9] less attention has been directed to whether the increased availability of large amounts of clinical data in the EHR can allow for more accurate risk assessment tools. The effectiveness of current tools is limited by the populations, datasets, and statistical tools that enabled their development.
Current risk prediction tools in America are based on cohort studies that use chart review and patient interviews to obtain high-quality data. They require personnel time to calculate, are based on particular patient populations with relatively limited sample sizes, and are difficult and expensive to update. 10 When used in external populations years after their initial development, the validity of these tools can be inconsistent. 10 However, an increasingly available electronic health record (EHR) may provide an opportunity to make internally developed risk tools that are more accurate and timely. 11, 12 Further, the use of EHRs is expected to increase rapidly with a recent multibillion dollar investment by the federal government. 13 Thus far, integrated and comprehensive EHR systems have seen limited use in clinical practice. 14 However, the Veterans Health Administration (VHA) is an exception, 15 and provides a unique opportunity for exploring the benefits and opportunities of EHR.
Clinical risk prediction also could benefit from concurrent progress in the development of flexible and adaptive (or "nonparametric") regression and machine learning methods, many of which are particularly well suited for large datasets with many variables. 16 For example, "ensemble methods" (which are also known as "metaclassifiers," and include random forests and boosting) work by incorporating predictions from a large number of small, simple models, and would have been computationally infeasible until relatively recently. These and related methods provide "automatic" prediction as they do not require the user to specify whether or how to include predictor variables, are robust to outliers, and limit overfitting by design. 16 In this study, we used EHR data across multiple VHA hospitals with flexible statistical methods to explore the extent to which risk prediction of fatal CCV events can be improved relative to traditional approaches. Specifically, we compared predictive performance using: (1) the Framingham Risk Score (FRS) versus internally developed EHR-derived models; (2) parametric versus nonparametric regression methodology; and (3) traditional risk predictors versus additional risk predictors obtainable from the VHA EHR (such as hypertensive medications and comorbid conditions).
METHODS

Data and Sample
We used data from patients treated at 12 VHA facilities in the midwestern United States from 2003 to 2007. The outcome of interest was CCV-related death within 5 years, and was determined using international classification of diseases-10 codes I00-I99 from the National Death Index. Unlike nonfatal CCV events, this outcome is available even for patients who discontinue care at VHA facilities.
Our eligibility criteria were based on those used by the Office of Quality and Performance for the VA External Peer Review Program. We included in our sample all patients over 18 years of age with at least 2 visits to a primary care, cardiology/hypertension, endocrine/diabetes, chronic infectious disease care, or mental health clinic during the baseline year (2003). The visit criterion was used to exclude patients who attend VHA facilities infrequently for prescription medication refills, while using outside facilities for clinical care. To ensure that patients did not have a recent history of cardiovascular disease, we excluded those with a known CCV diagnosis or event during the baseline year, using information from the VHA Medical SAS Data Sets. This makes the sample more comparable with that of the Framingham study. The table in Supplemental Digital Con-tent 1, http://links.lww.com/MLR/A408 shows the sample size for each inclusion criterion.
We obtained information on diagnoses from the VHA Medical SAS Data Sets, medication and laboratory data from the VHA Decision Support System files, and vital signs from the VHA Corporate Data Warehouse. For patients who had >1 recorded laboratory value, we used the average of the last 2 during the baseline year, and we considered biologically implausible values to be missing. We used international classification of diseases-9 codes to identify baseline status for clinical diagnoses that are also candidate predictors of CCV risk ( [17] [18] [19] [20] Diabetes status was also determined using pharmacy information (any insulin or oral hypoglycemic prescription fills). All risk predictor data were recorded during the baseline year, and missing values were singly imputed by chained equations. 21 More details about our data and about EHR data in the VHA in general are available in Supplemental Digital Content 2, Appendix A, http://links.lww.com/MLR/A409.
Prediction Methods
For our primary analyses, we compared 4 risk prediction methods: the FRS (which used Weibull regression), parametric logistic regression, nonparametric generalized additive modeling (GAM), and boosting (a nonparametric ensemble method) across 3 sets of predictors. See Figure 1 for a schematic summarizing the different types of prediction methods; we chose 1 representative method from each type. These 4 methods are all well established, but technically very different.
As mortality was the outcome of interest, we implemented the FRS that predicts CCV death. 22 This FRS is derived from a Weibull survival model including sex, age, systolic blood pressure (SBP), smoking status, total/highdensity lipoprotein cholesterol ratio, diabetes, and electrocardiogram (ECG)-left ventricular hypertrophy (ECG-LVH).
Smoking status and ECG-LVH were unavailable for our sample. The model assumed by FRS for the probability of CCV-related death within 5 years (denoted by Y ) is the following.
PðY ¼1 j X ¼xÞ¼1À exp À exp logð5ÞÀmðxÞ exp½yþy 1 mðxÞ
;
is the observed vector of predictors, j indexes the p elements of x, and b = (b 0 , b 1 ,y, b p ), y, and y 1 are parameters with specified values estimated from the Framingham cohort.
To tailor the FRS to our sample, we also estimated a "recalibrated" FRS that used the transformed FRS as a predictor in a logistic regression model. logit PðY ¼1 j X ¼xÞ¼a 0 þa 1 logð5ÞÀmðxÞ exp½yþy 1 mðxÞ
With a 0 and a 1 parameters estimated in our sample, and m(x) as defined previously. Logistic regression is by far the most popular method for general prediction of a binary outcome; it generally relies on exact specification of a parametric model. 16, 23 Our assumed logistic regression model was:
where the parameter vector g = (g 0 , g 1 ,y, g p ) was estimated in our sample. We log-transformed SBP, medication counts, number of visits during the baseline year, and serum creatinine, and otherwise assumed a linear relationship between predictors and log-odds of risk. We did not consider interaction terms, and no variable selection criteria were applied so all predictors were included. Logistic regression can be viewed as yielding a model similar to the FRS Weibull model, but with all coefficients tailored to our sample. GAM 24 is similar to standard logistic regression, except nonparametric functions f j of the predictors are estimated (via splines) instead of coefficients for linear terms. 16, 24 The assumed model is as follows.
where f 0 is an intercept term. We implemented GAM using the "gam" package in R, using default settings. As with our implementation of logistic regression, no variable selection criteria were applied and all predictors were included in each model. Boosting 25 is an "ensemble method" (or "meta-classifier") that combines many simple models (eg, trees with very few splits) fit to successively reweighted or resampled data using weights that increase the importance of previously misclassified data points. 16, 26, 27 Unlike previously discussed methods, boosting automatically performs variable selection and does not yield a simple regression formula that can be written out. We implemented gradient tree boosting using the "gbm" package in R with 500 two-level trees, thereby allowing all possible pairwise interactions.
More details and further explanation about GAM and boosting are available in Supplemental Digital Content 3, Appendix B http://links.lww.com/MLR/A410. We also used multivariate adaptive regression splines 28 and random forests 29 in secondary analyses. Results are available upon request.
Risk Predictors
We explored predictive performance across 3 subsets of risk predictors: (1) only the traditional risk predictors used to calculate the FRS; (2) the traditional risk predictors along with medication information; and (3) traditional risk predictors with medication information, laboratory values, vital signs, diagnoses, and other data (see Table 1 for a list of all candidate predictors).
Evaluation
We assessed discrimination and calibration of the 4 risk prediction methods using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow goodness-of-fit (HL-GOF) test, respectively, with 10-fold crossvalidation to penalize overfitting. 16, 30 We explored changes in estimated risk with a reclassification table and the net reclassification improvement (NRI) 31 using (0%-2%, 2%-5%, 5%-10%, 10%-20%, 20%-100%) risk groupings, and also present plots of the distributions of estimated risk.
All statistical analyses were conducted using R 32 and Stata. 33 
RESULTS
Patient Characteristics
The characteristics of the patients in the sample are shown in Table 1 . There were 113,973 patients in total and 4995 (4.4%) died within 5 years of CCV-related causes. Most patients (95.6%) were male and the mean age was 63.4 years (SD = 13.6 y). The rate of comorbidity was high, including high rates of diabetes (24.3%), chronic obstructive pulmonary disease (24.1%), hypertension treatment (68.9% prescribed at least 1 medication at baseline), and narcotic or opiate prescriptions (25.6%). Patients who died of CCV-related causes were on average 10.1 years older at baseline, FIGURE 1. Schematic of prediction methods. Nonparametric methods do not require exact specification of a model for the outcome. Ensemble methods incorporate predictions from many small and simple models applied to, for example, weighted or sampled versions of the data. Bolded methods are those used in this paper. CART indicates classification and regression tree; GAM, generalized additive model, MARS, multivariate adaptive regression splines; SVM, support vector machine.
45% more likely to have a diagnosis of diabetes, and more likely to be prescribed medications (26% more likely for hypertension and 47% more likely for diabetes). Table 2 shows cross-validated discrimination and calibration results. All estimates were calculated using conservative cross-validation methodology (with k = 10 folds) to penalize overfitting. Of note, the use of more predictor variables yielded larger increases in discrimination than the use of more flexible analytic methods. Using only traditional risk predictors, AUC increased from 71.3% for the FRS to 72.6% for logistic regression and to 73.1% for GAM and boosting. With more predictors the advantage of using nonparametric as opposed to logistic regression was magnified. For example, when using all selected predictors rather than just the traditional set, AUC increased by 3.7 points for logistic regression, 4.4 points for GAM, and 4.7 points for boosting. Discrimination and calibration results for multivariate adaptive regression splines and random forests were similar to those for GAM and boosting (available upon request). The FRS predicted only 3031 CCV-related deaths, compared with the 4995 that were actually observed (39.3% fewer). Calibration for the FRS (P < 0.001 for HL-GOF test) was particularly poor for low-risk patients; the FRS predicted 89.2% fewer deaths than observed for patients in the lowest quintile of risk. However, there was no evidence of poor calibration for the recalibrated FRS (HL-GOF, P = 0.236). Boosting also predicted fewer deaths than observed for lowrisk patients, but only when using all available data (P = 0.017 for HL-GOF test). The figure in Supplemental Digital Content 4, http://links.lww.com/MLR/A411 shows plots of observed versus expected numbers of events when using all predictors, as in traditional Hosmer-Lemeshow tables. Using a 5% risk threshold with all available predictors, cross-validated sensitivity was 42.4% for the FRS, 68.3% for logistic regression, 67.0% for GAM, and 63.6% for boosting; cross-validated specificity was 82.3% for the FRS, 71.1% for logistic regression, 73.8% for GAM, and 77.3% for boosting.
Discrimination and Calibration
To assess whether missing EHR data on smoking history could fully account for the underprediction of CCV events in the FRS, we performed a sensitivity analysis. Specifically, we examined the most favorable scenario for FRS by assuming every patient with a CCV-related death was a smoker and by randomly assigning a positive smoking status to 30% of the rest of the population. In this scenario, the number of CCV events predicted by FRS only increased to 3659 (26.8% fewer than observed), and the HL-GOF test still rejected at the 0.05 level (P < 0.001).
Reclassification and Distribution of Estimated Risk
To further examine the predictiveness and calibration of the models, we conducted reclassification analyses based on risk groups of 0%-2%, 2%-5%, 5%-10%, 10%-20%, and 20%-100% (Table 3 ). Internally developed models always yielded significantly improved net reclassification compared with the externally developed FRS, and nonparametric methods gave significant improvement over logistic regression. The largest NRI was for boosting relative to the FRS [NRI, 0.29; 95% confidence interval (CI), 0.27-0.32]. Compared with FRS, boosting reclassified 61.7% of those with an event to a higher risk group and 8.3% of those without an event to a lower risk group. The smallest NRI was for boosting relative to GAM (NRI, 0.07; 95% CI, 0.06-0.09); boosting only reclassified 15.6% of those with events to a higher risk group and 10.5% of those without events to a lower risk group, compared with GAM. NRI was not significant comparing the FRS with the recalibrated FRS (NRI, 0.00; 95% CI, À 0.02 to 0.02), indicating that recalibration did not achieve significantly better arrangement into the specified risk categories despite improved calibration.
Plots of estimated risk show the underestimation of the FRS for low-risk patients, along with the relative similarity among internally developed methods; these plots are shown in Supplemental Digital Content 5, http://links.lww.com/ MLR/A412. These findings do have clinical implications. For example, consider what would happen if aspirin were used for anyone with an estimated risk of >5%, and we could estimate risk using either the FRS or boosting. Using boosting, 12,568 people would be treated who would not have been treated under the FRS, and 5767 people would not be treated who would have been treated under the FRS. The boosting treatment regime would be more accurate, as 1366 of the 12,568 people (10.9%) who would have been treated only when using boosting went on to die of CCV-related causes, compared with only 203 of the 5767 (3.5%) who would have been treated only when using the FRS. Figure 2 shows the relationship between traditional risk predictors (ie, those used to calculate the FRS) and *Percentages in rows labeled "event" are among patients with CCV events; in rows labeled "no event" percentages are among patients without CCV events.
Relationships Between Predictors and Risk
w Numbers in the "lower risk" columns reflect patients reclassified into lower risk groupings (eg, 20%-100% to 10%-20%), whereas numbers in the "higher risk" columns reflect patients reclassified into higher risk groupings (eg, 0%-2% to 2%-5%). z For these results, the FRS uses only traditional predictors, whereas other methods use all available predictors. CCV indicates cerebrovascular and cardiovascular; CI, confidence interval; FRS, Framingham risk score; GAM, generalized additive model; NRI, net reclassification improvement. estimated risk of 5-year CCV-related death for reference patients whose other predictor values were set equal to their respective sample means (see Table 1 for specific values). We found that less flexible methods mischaracterized the association between some predictors and the risk of CCVrelated death. Most notably, the FRS assumes strong increasing relationships for SBP and cholesterol ratio, but in our sample these relationships were quite weak. Further, GAM and boosting showed evidence of a slight U-shaped risk profile for SBP (ie, patients with very low or very high SBP were at highest risk), but this was missed by logistic regression as it assumed linearity. Thus, not only would a different coefficient value for SBP in the FRS be appropriate for our data, but the SBP variable itself would require additional transformation to maximize model fit.
DISCUSSION
Risk prediction is recommended in the management of every class of clinical cardiovascular decision, including diagnostic testing, aspirin, cholesterol, and antihypertensive use, and has a 50-year history in cardiology practice. Despite this, the most commonly used risk scores are developed in selected populations, with limited sample sizes and risk predictors, and using rigid statistical tools. Using the VHA as an example, we have shown that some of these limitations can be overcome with use of the EHR and nonparametric regression techniques. Flexible risk models that are developed internally or "recalibrated" can greatly improve predictive performance in terms of both discrimination and calibration. The best way to achieve greater performance seems to be by including more risk predictors, even when using imperfect EHR data. Using nonparametric methods with traditional risk predictors gave modest improvements compared with parametric approaches, but larger improvements occurred when additional predictors were added. Differences between the nonparametric methods (GAM and boosting) were not definitive. Even greater improvements could become more apparent with larger datasets (allowing for consideration of more variables, interactions, and transformations) and with the automation of these prediction tools. Such automation would obviate the need for data FIGURE 2 . Estimated relationships between traditional predictors and cerebrovascular and cardiovascular (CCV) risk. Predictions were generated using only the traditional risk predictors (age, systolic blood pressure, cholesterol ratio, and diabetes status); risk was estimated across the middle 95% of observed values of the predictors of interest at the sample mean of all other predictors. FRS indicates Framingham risk score; GAM, generalized additive model. entry, and could facilitate rapid implementation and result in dramatic benefits to patient care. Our results did not have the benefit of large, expensive chart review or survey data but were comparable with those of larger studies. 34, 35 Our findings should be interpreted in the context of a number of limitations. First, this is a feasibility study and the models we developed require additional work before consideration for use in clinical practice. Second, although the quality of EHR data in the VHA is impressive relative to many other data sources, it is still imperfect. For example, some variables frequently had missing values, whereas others were missing completely (such as smoking status and ECG-LVH). The EHR design could make these data elements searchable and text searching techniques are rapidly improving. The exclusion of smoking status and ECG-LVH could negatively impact the FRS in particular, although data enhancements should presumably improve the performance of all methods, and sensitivity analyses suggested that increased performance of the FRS would be modest. Third, although we excluded patients with a recent CCV event, we did not have data to exclude all patients with any history of cardiovascular disease, which would make our sample more like the one in which the FRS was developed. Next, although our new data and methods improved prediction substantially, AUC was never more than 80%; some patients' risk will inevitably still be misclassified. Finally, although fatal CCV events are an important outcome, nonfatal cardiovascular events are more commonly assessed in the risk prediction literature. We chose this outcome partly because it is reliably available in VA data, unlike nonfatal CCV events.
This study also has a number of important strengths. First, we used a large dataset (over 100,000 patients), which is representative of a meaningful and sizable portion of the VHA population. Second, we used a reliable outcome derived from the National Death Index, which is not always the case for EHR research. Finally, we have meaningfully extended the literature on risk prediction by assessing both state-of-the-art methods and varying amounts of data.
To our knowledge, investigation of the dual impact of data quality and statistical methodology is rare. Those studies that have appropriately assessed the use of nonparametric methods did not focus on advantages of EHR, 36, 37 and a recent review 36 indicates that others typically made limited comparisons (eg, only between logistic regression and classification trees) or had methodological flaws (eg, no cross-validation). Although Wu et al 38 recently provided an excellent comparison of nonparametric methods in a machine learning context while also discussing EHR issues, they did not explicitly evaluate the benefit of using comprehensive EHR data versus only traditional risk predictors. Also, of the 2 nonparametric approaches they explored, 1 (support vector machines) gave poor performance and the other (AdaBoost) has an improved implementation. 16 Some of our findings were particularly surprising. For example, the U-shaped and weakened associations between blood pressure and cholesterol and CCV-related death are in strong distinction to most risk scores. Recognizing that our goal is prediction and not causal inference, we believe these associations could be because of the reported phenomenon of treat-ment lowering low-density lipoprotein and SBP more than CCV mortality. 39, 40 This study suggests a number of opportunities for future work, both with respect to methodology and implementation in clinical practice. Extending this work to larger databases, and adding changes over time and increased clinical data (such as diagnostic study results) could allow for substantially greater predictive accuracy. An exploration of nonfatal CCV events would be useful to determine whether the impact of flexible methods and more data on quality of prediction would change. Further, simulationbased cost-effectiveness studies could draw on our results to fully assess the practical benefit and feasibility of better risk prediction. Our study shows that, once the data exist, developing good risk scores is within the scope of most large health systems. In fact, the nonparametric methods explored here are no more difficult to implement than logistic regression and are accessible in freely available software. The greatest opportunity for future work, though is in clinical and policy implementation. The drive towards patient-centered, tailored care 41 will make risk prediction and personalization more important than ever.
The recent political incentives towards Accountable Care Organizations 42 and EHR 43 will lead to a radical increase in large clinical datasets that make within-population clinical risk prediction viable for many health care systems. Our results suggest that these health care systems could achieve better risk prediction by using internally developed models with EHR data and flexible statistical methodology.
